Sei Investments Co. Invests $1.38 Million in GeneDx Holdings Corp. (NASDAQ:WGS)

Sei Investments Co. bought a new position in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 18,012 shares of the company's stock, valued at approximately $1,384,000. Sei Investments Co. owned 0.07% of GeneDx as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in WGS. MCF Advisors LLC grew its position in shares of GeneDx by 107.7% during the 4th quarter. MCF Advisors LLC now owns 351 shares of the company's stock valued at $27,000 after purchasing an additional 182 shares in the last quarter. Global Retirement Partners LLC purchased a new position in GeneDx during the fourth quarter worth about $28,000. Evolution Wealth Advisors LLC bought a new position in GeneDx in the 4th quarter worth about $202,000. Victory Capital Management Inc. purchased a new stake in shares of GeneDx in the 4th quarter valued at about $209,000. Finally, Point72 DIFC Ltd purchased a new stake in shares of GeneDx in the 3rd quarter valued at about $220,000. Hedge funds and other institutional investors own 61.72% of the company's stock.

GeneDx Price Performance

WGS traded up $4.01 during midday trading on Friday, hitting $96.63. The stock had a trading volume of 856,334 shares, compared to its average volume of 672,104. GeneDx Holdings Corp. has a 1 year low of $8.63 and a 1 year high of $115.60. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The business has a fifty day moving average of $90.43 and a 200 day moving average of $78.11. The company has a market cap of $2.71 billion, a P/E ratio of -49.30 and a beta of 1.93.

Remove Ads

GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.66. The company had revenue of $95.64 million during the quarter, compared to analysts' expectations of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. As a group, equities analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on WGS. TD Cowen raised their target price on shares of GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research note on Tuesday, January 7th. The Goldman Sachs Group increased their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a report on Wednesday, February 19th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $72.33.

Insider Buying and Selling at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 922 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $94.72, for a total value of $87,331.84. Following the completion of the sale, the chief financial officer now owns 5,446 shares in the company, valued at approximately $515,845.12. The trade was a 14.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Katherine Stueland sold 1,657 shares of the firm's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36. Following the completion of the transaction, the chief executive officer now owns 3,937 shares in the company, valued at $308,975.76. This represents a 29.62 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 138,780 shares of company stock worth $12,907,437 over the last three months. Company insiders own 27.30% of the company's stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.